Inspire Medical Systems, Inc. (NYSE:INSP) Receives Average Recommendation of “Hold” from Analysts

Shares of Inspire Medical Systems, Inc. (NYSE:INSP) have earned an average rating of “Hold” from the nineteen analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $104.2353.

Several equities analysts recently commented on the company. Weiss Ratings reissued a “sell (d)” rating on shares of Inspire Medical Systems in a report on Monday, December 29th. JPMorgan Chase & Co. increased their target price on Inspire Medical Systems from $82.00 to $118.00 and gave the company a “neutral” rating in a report on Tuesday, December 16th. Evercore reissued an “outperform” rating on shares of Inspire Medical Systems in a report on Friday, February 27th. Oppenheimer lowered Inspire Medical Systems from an “outperform” rating to a “market perform” rating in a report on Thursday, January 22nd. Finally, Piper Sandler dropped their target price on Inspire Medical Systems from $165.00 to $85.00 and set an “overweight” rating on the stock in a report on Thursday, February 12th.

Institutional Trading of Inspire Medical Systems

Several institutional investors and hedge funds have recently made changes to their positions in the company. Rockefeller Capital Management L.P. lifted its holdings in shares of Inspire Medical Systems by 14.9% in the 4th quarter. Rockefeller Capital Management L.P. now owns 5,712 shares of the company’s stock valued at $527,000 after purchasing an additional 739 shares during the last quarter. Corient Private Wealth LLC purchased a new stake in shares of Inspire Medical Systems in the 4th quarter valued at about $354,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Inspire Medical Systems by 291.9% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,233 shares of the company’s stock valued at $390,000 after purchasing an additional 3,153 shares during the last quarter. Virtu Financial LLC lifted its holdings in shares of Inspire Medical Systems by 40.2% in the 4th quarter. Virtu Financial LLC now owns 5,712 shares of the company’s stock valued at $527,000 after purchasing an additional 1,639 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of Inspire Medical Systems by 181.7% in the 4th quarter. Invesco Ltd. now owns 261,374 shares of the company’s stock valued at $24,107,000 after purchasing an additional 168,587 shares during the last quarter. 94.91% of the stock is owned by hedge funds and other institutional investors.

Inspire Medical Systems Price Performance

NYSE:INSP opened at $53.35 on Thursday. The firm has a market capitalization of $1.54 billion, a PE ratio of 10.71, a price-to-earnings-growth ratio of 2.70 and a beta of 0.86. The business’s fifty day moving average price is $60.25 and its 200 day moving average price is $82.00. Inspire Medical Systems has a 12 month low of $48.30 and a 12 month high of $163.35.

Inspire Medical Systems (NYSE:INSP) last posted its earnings results on Wednesday, February 11th. The company reported $1.65 EPS for the quarter, beating the consensus estimate of $0.69 by $0.96. The firm had revenue of $269.08 million for the quarter, compared to analyst estimates of $264.02 million. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.Inspire Medical Systems’s revenue for the quarter was up 12.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.15 earnings per share. As a group, equities analysts anticipate that Inspire Medical Systems will post 2.16 EPS for the current year.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.